pGL4.0-TERT G250A Citations (4)

Originally described in: Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, Choi S, Hong C, He D, Pekmezci M, Wiencke JK, Wrensch MR, Chang SM, Walsh KM, Myong S, Song JS, Costello JF Science. 2015 May 29;348(6238):1036-9. doi: 10.1126/science.aab0015. Epub 2015 May 14. PubMed Journal

---

Articles Citing pGL4.0-TERT G250A

Articles
ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT. Bui CB, Le HK, Vu DM, Truong KD, Nguyen NM, Ho MAN, Truong DQ. Mol Carcinog. 2019 Nov;58(11):1998-2007. doi: 10.1002/mc.23091. Epub 2019 Jul 31. PubMed
Phase and context shape the function of composite oncogenic mutations. Gorelick AN, Sanchez-Rivera FJ, Cai Y, Bielski CM, Biederstedt E, Jonsson P, Richards AL, Vasan N, Penson AV, Friedman ND, Ho YJ, Baslan T, Bandlamudi C, Scaltriti M, Schultz N, Lowe SW, Reznik E, Taylor BS. Nature. 2020 Jun;582(7810):100-103. doi: 10.1038/s41586-020-2315-8. Epub 2020 May 27. PubMed
The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations. Xue J, Li S, Shi P, Chen M, Yu S, Hong S, Li Y, Liu R, Xiao H. Front Oncol. 2021 Jun 16;11:649323. doi: 10.3389/fonc.2021.649323. eCollection 2021. PubMed
GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. McKinney AM, Mathur R, Stevers NO, Molinaro AM, Chang SM, Phillips JJ, Costello JF. Cell Rep. 2022 Sep 20;40(12):111344. doi: 10.1016/j.celrep.2022.111344. PubMed

If you have published an article using this material, please email us at to have your article added to this page.